Pradaxa MDL Court Orders Establishment of Qualified Settlement Fund, Notes Rottenstein Law Group LLP - WSFA.com Montgomery Alabama news.

Pradaxa MDL Court Orders Establishment of Qualified Settlement Fund, Notes Rottenstein Law Group LLP

Posted:

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.

SOURCE:

The firm currently represents patients who allege that they have suffered serious side effects from use of anticoagulants Pradaxa and Xarelto.

Rockville Centre, NY (PRWEB) August 19, 2014

The Rottenstein Law Group, a national personal injury law firm that represents persons who believe they were injured by anticoagulants such as Pradaxa (http://www.rotlaw.com/pradaxa-lawsuit/) and Xarelto (http://www.rotlaw.com/xarelto/), has learned that the federal court overseeing the consolidated Pradaxa lawsuits has ordered the establishment of a qualified settlement fund and appointed an administrator of the fund.

According to Case Management Order Number 82, filed on August 13 in IN RE: PRADAXA (DABIGATRAN ETEXILATE) PRODUCTS LIABILITY LITIGATION (no. 3:12-MD-02385; U.S. District Court for the Southern District of Illinois), the federal multidistrict litigation consolidating Pradaxa lawsuits against drugmaker Boehringer Ingelheim Pharmaceuticals, Inc., a qualified settlement fund is established, and a fund administrator appointed, in order to effectuate the settlement of lawsuits as provided for by the earlier Master Settlement Agreement.

According to the order, the money to be deposited into the settlement fund is to be segregated into sub-accounts of $561 million, $50 million, $26 million, and $13 million; all the money totaling $650 million.

This is indeed encouraging, said Rochelle Rottenstein, principal of the Rottenstein Law Group, That money will certainly help to defray some of the expenses of those who have been harmed by Pradaxa. We can only hope that a similar arrangement will be made for those who have taken Pradaxas sister drug Xarelto.

In 2013, the U.S. FDA received several hundred adverse event reports submitted by individuals who claimed to have a serious adverse side effect while taking Xarelto (rivaroxaban) (http://www.rotlaw.com/xarelto/), as compared to a lower number for Pradaxa (dabigatran).** Data show that the number of persons being prescribed these blood thinning drugs is estimated at about 4 million for the year, with Xarelto prescriptions outnumbering Pradaxa prescriptions by two-to-one.** Anticoagulants (or blood thinners) are considered high-risk prescription drugs because they can cause excessive internal bleeding and other injuries in some patients.

Anyone needing more information about the dangers of Xarelto should visit the firms Xarelto site, where everything is explained in clear, concise language. Representatives of the firm are available to answer any questions, and there is a confidential, no-cost claim evaluation form that can be filled out in order to determine if there are grounds to file a Xarelto lawsuit.

**http://www.ismp.org/quarterwatch/pdfs/2013Q1.pdf

ABOUT THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)
Contact:

The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
100 Merrick Road
Suite 226W
Rockville Centre, NY 11570
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
https://plus.google.com/106070664376281033016/

For the original version on PRWeb visit: http://www.prweb.com/releases/pradaxa/lawsuits/prweb12103209.htm

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

Powered by WorldNow